Staging Preclinical Alzheimer’s Disease Pathologies

COMBINED tau biomarkers track early cognitive decline and forecast structural neurodegeneration in preclinical Alzheimer’s disease. Clinicians evaluating asymptomatic individuals with confirmed amyloid-beta deposition frequently face significant prognostic challenges due to variable disease trajectories. While plasma biomarkers offer high diagnostic sensitivity, they lack spatial precision regarding fibrillar protein localization in specific neural tissues. To address these practical limitations, a prospective multicenter clinical trial evaluated 330 cognitively unimpaired adults over an extended five-year tracking period to determine if integrating blood fluid assays with standard neuroimaging optimizes patient staging. All participants were confirmed to be amyloid-positive at baseline using florbetapir imaging to capture the early pathological changes.

Trajectories Across Preclinical Alzheimer’s Disease

The investigators stratified the asymptomatic sample using baseline plasma phosphorylated tau-217 levels along with standardized visual evaluations of approved flortaucipir positron emission tomography scans. Patients presenting with concordant positivity across both diagnostic modalities represented the highest-risk category within the classic neurodegenerative cascade. This positive-concordant subpopulation exhibited extensive baseline cortical amyloid burden, accelerated fronto-temporo-parietal tau protein dissemination, and severe gray matter volume loss over follow-up. Conversely, individuals demonstrating discordant biomarker profiles, such as elevated blood markers paired with negative visual scans, experienced much slower biological progression, suggesting either low-tau states or an early transitional phase.

Clinical Implications for Healthcare Providers

Longitudinal cognitive assessments using structured composite scoring tools confirmed that dual-biomarker concordance strongly correlates with severe cognitive decline over time. Path mediation analysis demonstrated that approximately 52% of the relationship between progressive tau aggregation and memory impairment is directly driven by structural cortical atrophy. For medical specialists, nuclear medicine physicians, and primary care providers, these findings indicate that binary classification is no longer sufficient for managing preclinical Alzheimer’s disease cases. Implementing a dual-biomarker strategy allows physicians to refine early risk prediction, identify optimal candidates for prevention trials, and strategically implement disease-modifying therapies prior to clinical symptom onset.

Reference

Labrador-Espinosa MA et al. Clinico-biological trajectories stratified by combined tau biomarkers in preclinical Alzheimer’s disease. Alzheimer’s Research & Therapy. 2026;18:154.

Featured Image: Framestock on Adobe Stock.